Bad blood: secrets and lies in a Silicon Valley startup

Book Cover
Average Rating
5 star
 
(1)
4 star
 
(0)
3 star
 
(0)
2 star
 
(0)
1 star
 
(0)
Publisher:
Varies, see individual formats and editions
Pub. Date:
Varies, see individual formats and editions
Language:
English
Description
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Also in This Series
More Like This
More Copies In Prospector
Loading Prospector Copies...
More Details
Contributors:
ISBN:
9781524731656
9780593105061
9781524731663
9780525642855
Reviews from GoodReads
Loading GoodReads Reviews.
Staff View

Grouping Information

Grouped Work IDbaef1559-c66a-350a-94da-a1c38154f67e
Grouping Titlebad blood secrets and lies in a silicon valley startup
Grouping Authorjohn carreyrou
Grouping Categorybook
Grouping LanguageEnglish (eng)
Last Grouping Update2022-10-02 03:48:57AM
Last Indexed2022-10-02 04:09:29AM

Solr Fields

accelerated_reader_point_value
0
accelerated_reader_reading_level
0
auth_author2
Damron, Will
author
Carreyrou, John
author2-role
Damron, Will
author_display
Carreyrou, John
available_at_aurora
Central
Tallyn's Reach
detailed_location_aurora
Central
Tallyn's Reach
display_description
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
format_aurora
Book
Book on CD
eAudiobook
eBook
format_category_aurora
Audio Books
Books
eBook
id
baef1559-c66a-350a-94da-a1c38154f67e
isbn
9780525642855
9780593105061
9781524731656
9781524731663
itype_aurora
Audiobook CD
Book
last_indexed
2022-10-02T10:09:29.558Z
lexile_score
-1
literary_form
Non Fiction
literary_form_full
Non Fiction
local_callnumber_aurora
338.7 Car
COMPACT DISC 338.7 Car
owning_library_aurora
Aurora Public Library
owning_location_aurora
Central
Tallyn's Reach
primary_isbn
9781524731656
publishDate
2018
publisher
Alfred A. Knopf
Books on Tape
Knopf Doubleday Publishing Group
Random House Audio
recordtype
grouped_work
subject_facet
Audiobooks
Case studies
DIGITAL COMPACT DISC
Fraud -- United States
Hematologic equipment industry -- United States
Holmes, Elizabeth, -- 1984-
New business enterprises -- Corrupt practices -- United States -- Case studies
Securities fraud -- United States -- Case studies
Theranos (Firm) -- History
True crime stories
title_display
Bad blood : secrets and lies in a Silicon Valley startup
title_full
Bad Blood Secrets and Lies in a Silicon Valley Startup
Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou
Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou
title_short
Bad blood
title_sub
secrets and lies in a Silicon Valley startup
topic_facet
Audiobooks
Business
Corrupt practices
Fraud
Hematologic equipment industry
History
Holmes, Elizabeth
New business enterprises
Nonfiction
Securities fraud
Technology

Solr Details Tables

item_details

Bib IdItem IdShelf LocCall NumFormatFormat CategoryNum CopiesIs Order ItemIs eContenteContent SourceeContent URLDetailed StatusLast CheckinLocation
ils:.b18523298.i2416656xTallyn's Reach338.7 Car1falsefalseAvailableOct 20, 2021tlrnf
ils:.b18523298.i24166583Central338.7 Car1falsefalseDue Oct 24, 2022Oct 16, 2021cennf
overdrive:5e6a98c7-5d22-4478-9f5e-7531c563bdaa-1Online OverDrive CollectionOnline OverDriveeBookeBook1falsetrueOverDriveAvailable Online
overdrive:c44c8fcb-0a91-461c-ab6d-08d6fe2234bf-1Online OverDrive CollectionOnline OverDriveeAudiobookAudio Books2falsetrueOverDriveAvailable Online
ils:.b18664660.i24565854CentralCOMPACT DISC 338.7 Car1falsefalseAvailableAug 10, 2021cenav
ils:.b18664660.i24566044Tallyn's ReachCOMPACT DISC 338.7 Car1falsefalseAvailableJul 22, 2019tlrav

record_details

Bib IdFormatFormat CategoryEditionLanguagePublisherPublication DatePhysical DescriptionAbridged
ils:.b18523298BookBooksFirst editionEnglishAlfred A. Knopf2018x, 339 pages ; 25 cm.
overdrive:5e6a98c7-5d22-4478-9f5e-7531c563bdaaeBookeBookEnglishKnopf Doubleday Publishing Group2018
overdrive:c44c8fcb-0a91-461c-ab6d-08d6fe2234bfeAudiobookAudio BooksEnglishBooks on Tape2018
ils:.b18664660Book on CDAudio BooksUnabridgedEnglishRandom House Audiop20189 audio discs (11 1/2 hr.) : digital ; 4 3/4 in.

scoping_details_aurora

Bib IdItem IdGrouped StatusStatusLocally OwnedAvailableHoldableBookableIn Library Use OnlyLibrary OwnedHoldable PTypesBookable PTypesLocal Url
ils:.b18523298.i2416656xOn ShelfAvailablefalsetruetruefalsefalsetrue0, 1, 3, 20, 4, 5, 6, 7, 8, 11
ils:.b18523298.i24166583Checked OutChecked Outfalsefalsetruefalsefalsetrue0, 1, 3, 20, 4, 5, 6, 7, 8, 11
overdrive:5e6a98c7-5d22-4478-9f5e-7531c563bdaa-1Available OnlineAvailable Onlinefalsetruetruefalsefalsefalse
overdrive:c44c8fcb-0a91-461c-ab6d-08d6fe2234bf-1Available OnlineAvailable Onlinefalsetruetruefalsefalsefalse
ils:.b18664660.i24565854On ShelfAvailablefalsetruetruefalsefalsetrue0, 1, 3, 20, 4, 5, 6, 7, 8, 11
ils:.b18664660.i24566044On ShelfAvailablefalsetruetruefalsefalsetrue0, 1, 3, 4, 20, 5, 6, 7, 8, 11